HBR-news-thumbnail

February 12 2021

In addition to the logistics challenges that have slowed the rollout of the highly effective Pfizer-BioNTech and Moderna Covid-19 vaccines, there is another obstacle that needs to be overcome: the  large  numbers of people — up to 40% of the U.S. population — who say they won’t get vaccinated.

Read the article.